Evidence map›Paper›PMID 29875212›Full record

ArticleBMJ (Clinical research ed.)2018

Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005.

Magdalena Zwierzyna, Mark Davies, Aroon D Hingorani, Jackie Hunter

Abstract read
In one paragraph

Article in BMJ (Clinical research ed.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Time to publication for results of clinical trials.The Cochrane database of systematic reviews · 2024
    Pooled it
  3. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2020 · on this map
    Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Determinants of publication likelihood and timeliness for clinical studies.Journal of clinical and translational science · 2026
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Magdalena ZwierzynaBenevolentBio Ltd, London NW1 1LW, UK.
Mark DaviesBenevolentBio Ltd, London NW1 1LW, UK.
Aroon D HingoraniInstitute of Cardiovascular Science, University College London, London, UK.
Jackie HunterBenevolentBio Ltd, London NW1 1LW, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the distribution, design characteristics, and dissemination of clinical trials by funding organisation and medical specialty.

designCross sectional descriptive analysis. DATA SOURCES: Trial protocol information from clinicaltrials.gov, metadata of journal articles in which trial results were published (PubMed), and quality metrics of associated journals from SCImago Journal and Country Rank database. SELECTION CRITERIA: All 45 620 clinical trials evaluating small molecule therapeutics, biological drugs, adjuvants, and vaccines, completed after January 2006 and before July 2015, including randomised controlled trials and non-randomised studies across all clinical phases.

resultsIndustry was more likely than non-profit funders to fund large international randomised controlled trials, although methodological differences have been decreasing with time. Among 27 835 completed efficacy trials (phase II-IV), 15 084 (54.2%) had disclosed their findings publicly. Industry was more likely than non-profit trial funders to disseminate trial results (59.3% (10 444/17 627)

conclusionsTrial design and dissemination of results vary substantially depending on the type and size of funding institution as well as the disease area under study.

Indexed as

Research Support as TopicClinical Trials as TopicCross-Sectional StudiesDisclosureDrug IndustryHumansInformation DisseminationPublic SectorPubMedRandomized Controlled Trials as TopicRegistriesResearch DesignResearch Report

Identifiers

PMID29875212
PMCPMC5989153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.